Filtered By:
Condition: SARS
Drug: Zithromax
This page shows you your search results in order of date.
Order by Relevance | Date
Total 191 results found since Jan 2013.
TWiV 1030: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses the use of RSV vaccines in older adults: recommendations of the advisory committee on immunization practices, case report of leprosy in Central Florida, blood group A enhances SARS-CoV-2 infection, predicting COVID-19 incidence using wastewater surveillance data, a common allele of HLA associated with asymptomatic SARS-CoV-2 infection, prevalence of low-frequency, antiviral resistance variants in SARS-CoV-2 isolates in Ontario, Canada, viral resistance analyses from the Remdesivir phase 3 adaptive COVID-19 treatment trial-1, impact of Molnupiravir treatment on patient-r...
Source: This Week in Virology - MP3 Edition - July 29, 2023 Category: Virology Authors: VIncent Racaniello Source Type: podcasts
Exploring the correlations between < em > epi < /em > indicators of COVID-19 and the concentration of pharmaceutical compounds in wastewater treatment plants in Northern Portugal
J Hazard Mater Adv. 2023 May;10:100315. doi: 10.1016/j.hazadv.2023.100315. Epub 2023 May 11.ABSTRACTThe COVID-19 pandemic caused by the SARS-CoV-2 virus led to changes in the lifestyle and human behaviour, which resulted in different consumption patterns of some classes of pharmaceuticals including curative, symptom-relieving, and psychotropic drugs. The trends in the consumption of these compounds are related to their concentrations in wastewater systems, since incompletely metabolised drugs (or their metabolites back transformed into the parental form) may be detected and quantified by analytical methods. Pharmaceuticals...
Source: Adv Data - May 16, 2023 Category: Epidemiology Authors: Ana R Silva Daniela P Mesquita M Salom é Duarte Ana R Lado Ribeiro M Fernando R Pereira M Madalena Alves S ílvia Monteiro Ricardo Santos M ónica V Cunha Sandra Jorge Joana Vieira Jo ão Vilaça Lu ísa C Lopes Marta Carvalho Carlos Brito Ant ónio Mart Source Type: research
Inhaled Budesonide for COVID-19 in People at Higher Risk of Complications in the Community: The UK National Community Randomi
Ann Fam Med. 2023 Jan 1;(21 Suppl 1). doi: 10.1370/afm.21.s1.3859.ABSTRACTBackground The effectiveness of repurposed treatments with supportive evidence for higher risk individuals with COVID-19 in the community is unknown. In the UK PRINCIPLE national platform trial we aimed to determine whether 're-purposed medicines' (hydroxychloroquine, azithromycin, doxycycline, colchicine, inhaled budesonide, and other interventions) reduced time to recovery and COVID-19 related hospitalisations/deaths among people at higher risk of COVID-19 complications in the community. We mainly report the findings for budesonide arm here. Method...
Source: Annals of Family Medicine - March 21, 2023 Category: Primary Care Authors: Richard Hobbs Oghenekome Gbinigie Emma Ogburn Ly-Mee Yu Oliver van Hecke Jienchi Dorward Chris Butler Benjamin Saville Source Type: research
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)
Ann Intern Med. 2022 Nov 29. doi: 10.7326/M22-2249. Online ahead of print.ABSTRACTDescription: Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data emerge on SARS-CoV-2 variants and the availability of newer treatments. The Scientific Medical Policy Committee (SMPC) of the American College of Physicians (ACP) developed these living, rapid practice points to summarize the best available evidence on the treatment of adults with confirmed COVID-19 in an outpatient setting. These practice points do not evaluate COVID-19 treatments in the inpatient setting or adjunctive COVID-19 treatments in t...
Source: Annals of Internal Medicine - November 28, 2022 Category: Internal Medicine Authors: Amir Qaseem Jennifer Yost Matthew C Miller Rebecca Andrews Janet A Jokela Mary Ann Forciea George M Abraham Linda L Humphrey Scientific Medical Policy Committee of the American College of Physicians Source Type: research
Outpatient Treatment of Confirmed COVID-19 : A Living, Rapid Review for the American College of Physicians
CONCLUSION: Some antiviral medications and monoclonal antibodies may improve outcomes for outpatients with mild to moderate COVID-19. However, the generalizability of the findings to the currently dominant Omicron variant is limited.PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42022323440).PMID:36442056 | DOI:10.7326/M22-2202
Source: Annals of Internal Medicine - November 28, 2022 Category: Internal Medicine Authors: Isolde Sommer Andreea Dobrescu Dominic Ledinger Isabel Moser Kylie Thaler Emma Persad Martin Fangmeyer Robert Emprechtinger Irma Klerings Gerald Gartlehner Source Type: research
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)
Ann Intern Med. 2022 Nov 29. doi: 10.7326/M22-2249. Online ahead of print.ABSTRACTDescription: Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data emerge on SARS-CoV-2 variants and the availability of newer treatments. The Scientific Medical Policy Committee (SMPC) of the American College of Physicians (ACP) developed these living, rapid practice points to summarize the best available evidence on the treatment of adults with confirmed COVID-19 in an outpatient setting. These practice points do not evaluate COVID-19 treatments in the inpatient setting or adjunctive COVID-19 treatments in t...
Source: Annals of Internal Medicine - November 28, 2022 Category: Internal Medicine Authors: Amir Qaseem Jennifer Yost Matthew C Miller Rebecca Andrews Janet A Jokela Mary Ann Forciea George M Abraham Linda L Humphrey Scientific Medical Policy Committee of the American College of Physicians Source Type: research
Outpatient Treatment of Confirmed COVID-19 : A Living, Rapid Review for the American College of Physicians
CONCLUSION: Some antiviral medications and monoclonal antibodies may improve outcomes for outpatients with mild to moderate COVID-19. However, the generalizability of the findings to the currently dominant Omicron variant is limited.PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42022323440).PMID:36442056 | DOI:10.7326/M22-2202
Source: Annals of Internal Medicine - November 28, 2022 Category: Internal Medicine Authors: Isolde Sommer Andreea Dobrescu Dominic Ledinger Isabel Moser Kylie Thaler Emma Persad Martin Fangmeyer Robert Emprechtinger Irma Klerings Gerald Gartlehner Source Type: research
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)
Ann Intern Med. 2022 Nov 29. doi: 10.7326/M22-2249. Online ahead of print.ABSTRACTDescription: Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data emerge on SARS-CoV-2 variants and the availability of newer treatments. The Scientific Medical Policy Committee (SMPC) of the American College of Physicians (ACP) developed these living, rapid practice points to summarize the best available evidence on the treatment of adults with confirmed COVID-19 in an outpatient setting. These practice points do not evaluate COVID-19 treatments in the inpatient setting or adjunctive COVID-19 treatments in t...
Source: Annals of Internal Medicine - November 28, 2022 Category: Internal Medicine Authors: Amir Qaseem Jennifer Yost Matthew C Miller Rebecca Andrews Janet A Jokela Mary Ann Forciea George M Abraham Linda L Humphrey Scientific Medical Policy Committee of the American College of Physicians Source Type: research
Outpatient Treatment of Confirmed COVID-19 : A Living, Rapid Review for the American College of Physicians
CONCLUSION: Some antiviral medications and monoclonal antibodies may improve outcomes for outpatients with mild to moderate COVID-19. However, the generalizability of the findings to the currently dominant Omicron variant is limited.PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42022323440).PMID:36442056 | DOI:10.7326/M22-2202
Source: Annals of Internal Medicine - November 28, 2022 Category: Internal Medicine Authors: Isolde Sommer Andreea Dobrescu Dominic Ledinger Isabel Moser Kylie Thaler Emma Persad Martin Fangmeyer Robert Emprechtinger Irma Klerings Gerald Gartlehner Source Type: research
Azithromycin use in Covid- 19: A tale of changing guidelines
J Family Med Prim Care. 2022 Jul;11(7):3399-3400. doi: 10.4103/jfmpc.jfmpc_49_22. Epub 2022 Jul 22.ABSTRACTIt has been more than two years since the arrival of Covid-19 pandemic on world stage. When we look back during landmark events of last two years, several ones stand out. And one of these is utilization and then going out- of- favor of use of an antibiotic - Azithromycin. Pilva- a Croatian pharmaceutical company- headquartered in Zagreb in late 1970s discovered the drug. Then several years of research yielded a product which was highly effective and provided good therapeutic results. As this was a small company having...
Source: Primary Care - November 17, 2022 Category: Primary Care Authors: Harish Gupta Source Type: research
